SLC16A1 and neoplasm: Preclinical studies have demonstrated the potential of MCT inhibitors, such as AZD3965 (MCT1-specific) and syrosingopine (dual MCT1/MCT4), to reduce tumor growth and improve immunotherapy efficacy (44, 95, 96).